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 This paper describes the first genome wide association study of thromboxane A2 formation. 
 It shows that 5 SNPs in two genes, PPARGC1B and CNTN4, are associated with elevated 
thromboxane A2 formation in 806 Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) 
participants and with an excess of cardiovascular events in an independent ASCOT 
population (n=6,199).  
 Results indicate specific protection of aspirin for PPARGC1B and CNTN4. If confirmed, 








































































Background and aims: Elevated urinary 11-dehydro thromboxane B2 (TxB2), a measure of 
thromboxane A2 formation in vivo, predicts future atherothrombotic events. To further understand 
this relationship, the genetic determinants of 11-dehydro TxB2 and their associations with 
cardiovascular morbidity were investigated in this study. 
 
Methods and Results: Genome-wide and targeted genetic association studies of urinary 11-dehydro 
TxB2 were conducted in 806 Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) participants. The 
strongest associations were in PPARGC1B (rs4235745, rs32582, rs10515638) and CNTN4 
(rs10510230, rs4684343) – these 5 single nucleotide polymorphisms (SNPs) were independently 
associated with 11-dehydro TxB2 formation. Haplotypes of 11-dehydro TxB2 increasing alleles for 
both PPARGC1B and CNTN4 were significantly associated with 11-dehydro TxB2, explaining 5.2% and 
4.5% of the variation in the whole cohort, and 8.8% and 7.9% in participants not taking aspirin, 
respectively. In a second ASCOT population (n=6,199), addition of these 5 SNPs significantly 
improved the covariate-only cox proportional hazards model for cardiovascular events (chisq=14.7, 
P=0.01). Two of the risk alleles associated with increased urinary 11-dehydro TxB2 were individually 
associated with greater incidences of cardiovascular events - rs10515638 (HR =1.31, P=0.01) and 
rs10510230 (HR=1.25, P=0.007); effect sizes were larger in those not taking aspirin. 
 
Conclusions: PPARGC1B and CNTN4 genotypes are associated with elevated thromboxane A2 
formation and with an excess of cardiovascular events. Aspirin appears to blunt these associations.  
If specific protection of PPARGC1B and CNTN4 variant carriers by aspirin is confirmed by additional 
studies, PPARGC1B and CNTN4 genotyping could potentially assist in clinical decision making 
regarding the use of aspirin in primary prevention. 
 





































































Thromboxane A2 (TxA2) is a potent platelet agonist formed during platelet activation and contributes 
to the risk of arterial thrombosis [1]. Aspirin exerts its major antithrombotic effect by irreversibly 
acetylating platelet cyclo-oxygenase-1 (COX-1), inhibiting production of TxA2. In high risk patients, 
low-dose aspirin reduces the risk of major cardiovascular events by about 20% [2]. Direct 
measurement of TxA2 is not feasible as it is rapidly metabolised in vivo to its stable metabolite, 
thromboxane B2 (TxB2). Measurement of plasma or urinary levels of 11-dehydro TxB2 by mass 
spectrometry gives an accurate reflection of in vivo TxA2 production [3,4]. Increased urinary 11-
dehydro TxB2 concentration is an independent predictor of atherothrombotic events even in aspirin-
treated patients [5,6]. 
 
Measures of TxA2, including urinary [7] and plasma [8] 11-dehydro TxB2 have been shown to be 
heritable in Caucasian populations off and on aspirin (h2 = 0.5-0.7 and 0.2-0.4 respectively). Genetic 
studies have largely focused on the influence of the functional COX-2 single nucleotide 
polymorphism (SNP) rs20417 (–765G>C) on cardiovascular endpoints; a recent meta-analysis 
(n=49,232) reported the minor allele was associated with reduced risk of cardiovascular events and 
lower urinary 11-dehydro TxB2 [9]. 
 
To more comprehensively assess genetic contribution to TxA2 levels, we conducted genome-wide 
and targeted genetic association studies of urinary 11-dehydro TxB2 in a subset of participants from 
the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). In addition, we investigated whether 
variants associated with elevated 11-dehydro TxB2 levels increased the risk of atherothrombotic 








































































The ASCOT trial was a randomized, multicentre trial comparing the long-term effects of two 
antihypertensive regimens on myocardial infarction [10]. The population characteristics, genotyping, 
and imputation of the subsets of ASCOT participants investigated in this study are described in full in 
supplementary material online. All patients gave written informed consent. Written informed 
consent and approval by local research ethics committees and/or institutional review boards were 
obtained for ASCOT, the ASCOT DNA Repository, and the Hypertension Associated Cardiovascular 
Disease (HACVD) sub-study.  
 
Genotypes Associated with Elevated Thromboxane A2: 
Fasting urinary 11-dehydro TxB2 was measured by mass spectrometry in 1,006 participants of the 
HACVD sub-study [11] of the ASCOT trial, and expressed as pg 11-dehydro TxB2 /mg creatinine to 
normalize for urinary output. Genotyping was performed using the genome-wide Illumina 
HumanCNV370-Duo array (CNV370) and/or the Illumina HumanCVD BeadChip (CVD50k, targeting 
>2,000 genic regions related to cardiovascular disease (CVD)), and quality control exclusions applied 
as described previously [12, 13]. After further excluding all copy number variant (CNV) markers and 
SNPs with minor allele frequency (MAF) <5%, 272,166 genotyped SNPs (2,031,499 including imputed 
SNPs) on the CNV370 chip and 31,570 SNPs on the CVD50K chip were analysed in n=777 and n=544 
individuals with 11-dehydro TxB2 measurements, respectively (Supplementary Figure 1). 
 
For each SNP, a linear regression was performed of genotype (assuming an additive genetic model) 
on urinary 11-dehydro TxB2 level (a continuous trait) in PLINK v1.07 [14]. Unless otherwise stated, 
analyses were adjusted for the covariates: age, sex, smoking habit (current smokers vs. never & ex-
smokers), presence of type 2 diabetes, systolic blood pressure (SBP), body mass index (BMI), high 




































































reported aspirin use, study location (UK/Ireland or Scandinavia), and the first ten vectors from 
ancestry principal component analysis to avoid confounding due to population stratification. The 
11-dehydro TxB2 measurement was log transformed to an approximately normal distribution prior to 
analysis and quantile-quantile plots did not indicate any inflation of the test statistics 
(Supplementary methods and Supplementary Figures 2 and 3). 
 
Haplotypes were imputed in PLINK using the standard E-M algorithm. Bonferroni threshold for the 
CNV370 chip was P=1.8E-07 (0.05/272,166 genotyped SNPs) to account for multiple testing with a 
5% false positive rate. As many SNPs on the dense CVD50K chip are correlated, correction for the 
21,180 effective tests on the chip is appropriate [13], resulting in a Bonferroni threshold of P=2.4E-
06 (0.05/21,180). SNPs associated at P<1E-03 were considered suggestive of association on both 
chips. 
 
Effect of PPARGC1B and CNTN4 genotypes on Cardiovascular Event Free Survival:  
All ASCOT participants with DNA (n=9,063) were considered for inclusion in the survival analysis. The 
following exclusions were applied: study participants with prior cardiovascular event at baseline 
(n=1,382), other non- ischemic/haemorrhagic event during the study (n=342), self-declared non-
European ancestry (n=370), missing phenotype data or DNA (n=770) (Supplementary Figure 1). The 5 
SNPs independently associated with 11-dehydro TxB2 were successfully genotyped in 6,199 
participants (n=3,369 from Scandinavian centres and n=2,851 from UK/Ireland centres). The primary 
endpoint was a composite endpoint including all ischaemic cardiovascular events and procedures, 
defined as any of: fatal and non-fatal myocardial infarction (MI), fatal and non-fatal heart failure, 
fatal and non-fatal ischaemic stroke and transient ischaemic attack, angina (stable and unstable), 
peripheral arterial disease, revascularization procedures, and retinal vascular thrombosis. Where 
participants had multiple events, the earliest qualifying event was used. The study was stopped after 




































































mortality and stroke outcomes. Study participants with no qualifying event were censored at the 
earlier of the date of withdrawal from the study or the date of study termination (median, range: 5.7 
[1.1-7.1] years).  
 
Survival analyses were conducted using the R packages ‘survival’ version 3.2.0 and ‘survivalROC’ 
version 1.0.3 [15]. The proportional hazards assumption was met for all variables (Supplementary 
Table 1). Multivariate Cox proportional hazards models were used to collectively analyse all clinical 
covariates which were associated with the endpoint of cardiovascular event free survival, plus all 
genotypes. Chi square comparison of the log likelihoods from the covariates-only and full (covariates 
plus SNPs) model was used to test the alternative hypothesis that the addition of thromboxane-
associated SNPs would significantly improve the risk model for CV events. We hypothesized that 
genotypes associated with increased urinary 11-dehydro TxB2 in the association study would be 
inversely correlated with cardiovascular event-free survival, therefore P values and confidence 




Genotypes Associated with Elevated Thromboxane A2. 
Baseline characteristics of the cohort are shown in Table 1. Approximately half of the patients 
reported taking aspirin at the time of urinary 11-dehydro TxB2 measurement. As expected, 11-
dehydro TxB2 levels were significantly lower in those on aspirin.  
 
Manhattan plots (Figure 1) show that none of the SNPs was individually associated with 11-dehydro 
TxB2 level beyond Bonferroni threshold. There were no associations between COX-1 (PTGS1) and 
COX-2 (PTGS2) SNPs and 11-dehydro TxB2 in this study, even at the suggestive level (P<1E-03, 





































































Analysis of CVD50K chip: a PPARGC1B haplotype is significantly associated with 11-dehydro TxB2 
The strongest association signal from the CVD50K chip was in the PPARGC1B (peroxisome 
proliferator-activated receptor gamma, coactivator 1 beta) gene (Figure 1), where 14 SNPs were 
suggestive of association with 11-dehydro TxB2 (Supplementary Table 3). The most significant SNP at 
this locus was rs4235745 (P=4.3E-06, Table 2). Conditioning on rs4235745 genotype, two SNPs 
(rs32582 and rs10515638) remained associated with 11-dehydro TxB2 and were not correlated with 
each other (r2=0.15, Supplementary Table 4, Supplementary Figure 4). Although rs4235745 and 
rs32582 were not genotyped on the CNV370 chip, other variants in the gene did show some 
evidence of association with 11-dehydro TxB2 (Supplementary Table 5 and Figure 1). 
 
The haplotype of 11-dehydro TxB2-increasing alleles of the three independently associated SNPs 
(TTA, frequency 6%) was significantly associated with an increase of 382pg/mg creatinine 11-
dehydro TxB2, surpassing Bonferroni threshold (P=2.0E-06, Table 2). This haplotype explained 5.2% 
of the variation in 11-dehydro TxB2 in all subjects, 8.8% in subjects not on aspirin, and 1.8% in those 
on aspirin (multiple R2 values calculated in R). The 11-dehydro TxB2-decreasing alleles haplotype 
(GCC, frequency 66%) was associated with a decrease of 146pg/mg creatinine (Supplementary Table 
6). 
 
Analysis of CNV370 chip: a CNTN4 haplotype is significantly associated with 11-dehydro TxB2. 
The strongest association signal from the CNV370 analysis was in the CNTN4 (contactin 4) gene 
(Figure 1), where 13 SNPs were suggestive of association with 11-dehydro TxB2 (Supplementary 
Table 7). The most significant genotyped SNP at this locus was rs10510230 (P=5.1E-07, Table 2) and 
conditioning on this genotype revealed one other SNP, rs4684343, independently associated with 
11-dehydro TxB2 and not correlated with rs10510230 (r
2 =0.09, Supplementary Table 8 and 




































































(rs1171387), and this SNP is not very close to either of the top hit CNTN4 SNPs (rs10510230 or 
rs4684343). Hence there was very little signal at the CNTN4 gene on the CVD50K chip 
(Supplementary Table 5 and Figure 1). 
 
The haplotype of both 11-dehydro TxB2–increasing alleles of rs10510230 and rs4684343 (CG, 
frequency 13%) was significantly associated with increased 11-dehydro TxB2, surpassing Bonferroni 
threshold (P=2E-09, Table 2). This haplotype explained 4.5% of the variation in 11-dehydro TxB2 in all 
subjects, 7.9% for subjects not on aspirin, and 1.5% for those on aspirin. The 11-dehydro TxB2-
decreasing alleles haplotype (AA, frequency 44%) was associated with a decrease of 128pg/mg 
creatinine (Supplementary Table 9). 
 
Interaction with aspirin 
The five independently associated PPARGC1B and CNTN4 SNPs showed evidence for interaction with 
aspirin use in a model including the main SNP and aspirin effects and all covariates, with a greater 
association between genotype and 11-dehydro TxB2 in those not taking aspirin (Figure 1, Table 2, 
Supplementary Tables 10 and 11). The interaction was significant for three of these five SNPs after 
correction for multiple testing (P value threshold <0.01; interaction P-values for PPARGC1B SNPs: 
rs4235745 (P=3.3E-04), rs32582 (P= 3.0E-04), rs10515638 (P=0.02) and for CNTN4 SNPs: rs4684343 
(P=0.02), rs10515638 (P= 6.6E-05); Supplementary Tables 10 and 11.  
 
Function of 11-dehydro TxB2 – associated CNTN4 and PPARGC1B SNPs 
None of the independently associated SNPs nor their proxies were in exonic or predicted functional 
regions using the ensemble variant effect predictor (http://www.ensembl.org/Tools/VEP), nor were 
they associated with expression of any genes in any tissues in the GTEx portal 





































































Effect of PPARGC1B and CNTN4 genotypes on Cardiovascular Event Free Survival.  
Demographic and clinical characteristics of the survival analyses population are shown in Table 1. 
 
Addition of the 11-dehydro TxB2-associated genotypes improves survival model. 
The three PPARGC1B and two CNTN4 independently associated SNPs which comprised the 
haplotypes significantly associated with 11-dehydro TxB2 were included in the survival analysis. The 
addition of these five SNPs significantly improved the covariates-only Cox proportional hazards 
model of cardiovascular event free survival (chisq comparison of the log likelihoods P=0.01, Table 3).  
 
None of the SNPs were associated with any of the cardiovascular risk factors with the exception of a 
slightly increased risk of type 2 diabetes in rs32582 and rs10510230 carriers (Supplementary Table 
13). Results of the univariate survival analysis (Supplementary Table 14) were consistent with those 
reported in the multivariate analysis. There was a small sample overlap between the genetic 
association study and the survival analysis; when these individuals were excluded from the survival 
sample in a sensitivity analysis, it did not alter the overall results (Supplementary Table 15). 
 
 
Two SNPs independently associated with risk of event 
After Bonferroni correction for the 5 SNPs tested (P value threshold <0.01), rs10515638 (PPARGC1B) 
and rs10510230 (CNTN4) were associated with increased risk of event in multivariate (P=0.01 and 
6.9E-03 respectively) and univariate (P=0.03 and P=8.5E-03 respectively) survival models. The 
magnitudes of effect on survival associated with carriage of each minor allele of rs10515638 
(PPARGC1B, HR=1.31) and rs10510230 (CNTN4, HR=1.25) were similar to or greater than those 
associated with increments of 10 years age, 20 mmHg systolic BP, 1 mmol LDL-cholesterol, a 
diagnosis of diabetes mellitus, or use of amlodipine-based antihypertensive therapy in this cohort 





































































Stratification by aspirin use 
Kaplan Meier plots of survival analysis stratified by aspirin use for the two significant SNPs show that 
effect sizes were larger in subjects not taking aspirin compared to those on aspirin (Figure 2 and 
Supplementary Table 16) and survival receiver operating characteristic (ROC) curves showed that 
addition of the SNPs improved the area under the curve (AUC) for the all subjects and subjects not 
on aspirin samples, but not for those on aspirin (Supplementary Figure 5). However, when 
Aspirin:SNP interaction terms were added to the multivariate survival analysis, none were significant 
beyond correction for multiple testing (Supplementary Table 17). 
 
Stratification by type of event 
Comparing the separate stroke and coronary event analyses, the PPARGC1 SNP (rs10515638) had a 
larger effect size for coronary events (HR 1.41, P=0.002, 433 events) than for stroke events. By 
contrast, despite much lower power in the stroke analysis, the CNTN4 SNP (rs10510230) had a larger 
effect size for stroke (1.31, P=0.17, 57 events) than for coronary events, especially in those not on 
aspirin (HR 2.71, P=0.003, 26 events), Supplementary Table 18. 
 
The 11-dehydro TxB2-associated haplotypes are associated with cardiovascular event free survival. 
Survival analysis of the PPARGC1B and CNTN4 haplotypes which were associated with the highest 
11-dehydro TxB2 levels (Supplementary Table 19 and Supplementary Figure 6) showed that 
carriership of one copy of the PPARGC1B haplotype (HR= 1.21, P=0.05) and of the CNTN4 haplotype 
(HR=1.33, P=0.005), had similar effect sizes on survival to those of the highest effect size SNPs in the 







































































Association analysis of genome-wide and targeted, CVD-based genotype data revealed that a 3-SNP 
haplotype of PPARGC1B and a 2-SNP haplotype of CNTN4 are significantly associated with urinary 
levels of 11-dehydro TxB2, a surrogate measure for thromboxane A2 in the HACVD cohort. The 5 
constituent PPARGC1B/CNTN4 SNPs were genotyped in a second ASCOT cohort, and addition of 
these genotypes to clinical and demographic covariates significantly improved the Cox proportional 
hazards model of cardiovascular event-free survival, with 11-dehydro TxB2-increasing alleles 
associated with reduced event-free survival. In both the genetic association and the survival 
analyses, stratification by aspirin use showed that most of the genetic associations were more 
prominent in those not on aspirin. This may suggest that the genetic variants are primarily 
associated with COX1-synthesized thromboxane A2.  
 
Unfortunately, suitable data were not available to formally replicate the genetic associations with 
11-dehydro TxB2 in an independent cohort. However, our finding that the 11-dehydro TxB2-
increasing alleles of the same genetic variants increase the risk of cardiovascular events in an 
independent population does support our finding that these variants are associated with increased 
11-dehydro TxB2, (an established cardiovascular risk factor). In addition, Mendel’s observation that 
inheritance of one trait should be independent of the inheritance of other traits asserts that it is 
unlikely the same SNPs would be associated with both 11-dehydro TxB2 and CHD unless the 
phenotypes are causally linked. Therefore our finding that the same SNPs are associated with 
increased 11-dehydro TxB2 and increased risk of cardiovascular event (unconfounded by association 
with other measured cardiovascular risk factors) supports a causal relationship between 11-dehydro 
TxB2 and CHD and strengthens the finding by Eickelboom et al that urinary 11-dehydro TxB2 is an 
independent risk factor for atherothrombotic events. Whether the atherosclerosis causes the 





































































All five 11-dehydro TxB2-associated SNPs and their proxies are intronic. They are not in strong LD 
with neighbouring genes and it appears likely therefore that these tagging SNPs implicate PPARGC1B 
and CNTN4, however substantial further work is required to ascertain the true causal variants 
behind the association signals.  
 
The PPARGC1B gene is a member of the peroxisome proliferator-activated receptor gamma 
coactivator-1 (PGC-1) family, along with its homologue, PPARGC1A, and more distant relative PGC-1–
related coactivator (PRC). PPARGC1B and PPARGC1A appear to have overlapping function and they 
exhibit shared, wide tissue expression, especially in heart, skeletal muscle, brain and brown adipose 
tissue [16]. A variety of metabolic programs are regulated by PGC-1s, including in the heart where 
PGC-1s help maintain energy homeostasis and activate a broad program of angiogenic factors [17]. 
PGC-1s can co-activate a large range of transcription factors, including the nuclear receptor PPAR γ 
(Supplementary Figure 7) which plays an important role in metabolism, is anti-atherosclerotic and 
anti-inflammatory, and regulates the expression of many genes involved in atherosclerosis including 
COX-2 [18, 19]. Regulation of COX-2 expression by PPAR γ signalling may be the mechanism whereby 
polymorphisms in PPARGC1B influence thromboxane A2 levels. However, the larger effect size in 
subjects not on aspirin suggest the effect is more likely mediated by the primary aspirin target, COX-
1, or alternatively through influencing substrate availability or enzymes downstream of COX-1 in the 
thromboxane A2 synthetic pathway. It is not known whether PGC-1/ PPAR γ signalling effects 
expression of COX-1.   
 
Contactin 4 is a member of the immunoglobulin superfamily and is a known neuronal membrane cell 
adhesion molecule. CNTN4 expression has been shown in many tissue types other than neuronal, 





































































We conducted a search of the term ‘cardiovascular in the NHGRI-EBI GWAS catalogue-
(https://www.ebi.ac.uk/gwas/search?query=cardiovascular, accessed 25/10/17, Supplementary 
Table 20) in order to put our findings in the context of the vast GWAS data now available. The 
CNTN4 gene has been associated with serum uric acid levels in previous genome-wide association 
and linkage studies, [21, 22], which is itself correlated with a variety of CVD risk factors. There is 
some evidence for cross talk between COX and uric acid pathways - uric acid has been shown to 
stimulate COX-2 synthesis [23], for example. Although PPARGC1B does not feature in the GWAS 
catalogue results, genetic polymorphisms in the PPARGC1B genes have previously been putatively 
associated with type 2 diabetes [24, 25].  
 
A search of the five 11-dehydro TxB2 SNPs reported in this study in GWAS central, 
(http://www.gwascentral.org/ accessed 25/10/17), showed that none of the five SNPs have been 
included in GWAS of MI in this catalogue (Supplementary Table 21). Some of the SNPs have shown 
previous nominal associations (P<0.05) with other cardiovascular phenotypes, including associations 
between rs32583 and ischemic stroke (Supplementary Table 21). It should be noted that the five 11-
dehydro TxB2 -associated SNPs in this study were not present on most of the commonly used GWAS 
chips; rs4235745 for example is only on the IBC (CVD50K) chip (Supplementary Table 5). In addition, 
the thromboxane pathway represents one of many risk factors for a cardiovascular disease; 
therefore, we would not necessarily expect the SNPs reported here to be among the top GWAS hits 
for CVD. 
 
Identification of the genetic determinants of thromboxane A2 levels will help to improve our 
understanding of the physiology of this important prothrombotic agent. They may also prove to be 
useful biomarkers for assessing thromboxane levels without the need for urinary thromboxane 




































































by additional studies, PPARGC1B and CNTN4 genotyping could potentially assist in clinical decision 
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Table 1. Baseline characteristics  
Baseline characteristics of the genetic 















Age, years (mean±sd) 64.7±8.1 64.2±8.1 65.2±8.09 0.09 
Male (n,%) 626(78%) 336(81%) 290(74%) 0.02 
Current smoker (n,%) 186(23%) 94(23%) 92(23%) 0.77 
Current diabetes (n,%) 150(19%) 55(13%) 95(24%) 6.00E-05 
SBP, mmHg (mean±sd) 135.2±12.0 133.1±12.5 137.4±12.5 2.00E-07 
BMI, kg/m
2
 (mean±sd) 29.2±4.7 29.1±4.7 29.3±4.8 0.53 
HDL, mmol/L (mean±sd) 1.3±0.3 1.3 ± 0.4 1.3±0.3 0.16 
LDL, mmol/L (mean±sd) 3.0±0.9 3.0 ± 0.9 3.0±0.8 0.17 
Amlodipine treatment group (n,%) 407(50%) 215(52%) 192(49%) 0.44 
Baseline characteristics of the survival cohort 
(n=6,199) 








Age, years (mean±sd) 61.8±8.4 61.2±8.4 63.0±8.1 2.40E-15 
Male (n,%) 4,996(80.6) 3,470(79.7) 1,526(82.7) 5.70E-03 
Current smoker (n,%) 2,007(32.4) 1,525(35.0) 482(26.1) 1.00E-11 
Diabetes, type 2 (n,%) 1,404(22.6) 894(20.5) 510(27.6) 1.10E-09 
SBP, mmHg (mean±sd) 152.7±14.7 153.3±14.9 151.2±14.2 5.40E-07 
BMI, kg/m
2
 (mean±sd) 28.9±4.6 28.8±4.6 29.2±4.6 9.90E-04 
HDL, mmol/L (mean±sd) 1.28±0.34 1.30±0.34 1.25±0.32 1.60E-06 
LDL, mmol/L (mean±sd) 3.79±0.91 3.78±0.89 3.81±0.95 0.4 
UK/Ireland cohort (n,%) 2,830(45.6) 1,534(35.2) 1,296(70.3) <2.2E-16 




































































Follow-up, years (median, IQR) 5.6(5.1-6.0) 5.7(5.2-6.1) 5.5(5.0-6.0) 6.60E-15 
n events (composite endpoint) 477(7.7) 189(4.3) 288(15.6) <2.2E-16 






   -Coronary revascularisation procedure (n) 149 55 94 <2.2E-16 
   -Non-fatal MI (incl. silent) + fatal CHD (n) 271 108 163 <2.2E-16 
   -Ischemic stroke (n) 44 15 29 9.20E-08 
   -Other (n) 13 11 2 0.46 
Amlodipine treatment group: membership of amlodipine (vs atenolol) regime. SBP: Systolic blood 
pressure; BMI: Body mass index; HDL: High density lipoprotein; LDL: Low-density lipoprotein. 
UK/Ireland: UK/Ireland (vs Scandinavian) centres. Composite endpoint: total ischaemic 
cardiovascular events/procedures as described in methods. MI: myocardial infarction. CHD: coronary 
heart disease. IQR: Inter quartile range; SD: Standard deviation; 95% CIs for events were calculated 
using an exact Poisson test.  P:  comparison of on-aspirin and not-on-aspirin groups (Student's t-test 
or Mann-Whitney U test for normally and non-normally distributed variables respectively, or 





















































Table 2. PPARGC1B and CNTN4 SNPs independently associated with 11-dehydro TxB2.   
PPARGC1B            all subjects (n=544) 
subjects not on aspirin 
(n=276) 
subjects on aspirin 
(n=268) 
Chr SNP Position MAF A1/2  r
2
   D' beta P P 
SNP*Asp
 beta P beta P 
5 rs10515638 intron 1 0.08 T/G 0.07 0.58 233.1  7.30E-04 0.02 391.9 1.90E-03 74.7 0.12 
5 rs4235745 intron 1 0.3 T/C NA NA 166.7 4.30E-06 3.30E-04 284.9 2.20E-05 50.5 0.06 
5 rs32582 intron 2 0.18 A/C 0.42 0.93 201.1 9.10E-06 3.00E-04 353.1 2.10E-05 45.4 0.18 
3-SNP minor allele 
haplotype 
0.06 TTA     382.4 2.10E-06   658.7 9.50E-06 105.5 8.00E-02 
CNTN4           all subjects (n=772) 
subjects not on aspirin 
(n=396) 
subjects on aspirin 
(n=376) 
Chr SNP Position MAF A1/2  r
2
   D' beta P P 
SNP*Asp
 beta P beta P 
3 rs10510230 intron 1 0.15 C/A NA NA 189.8 5.10E-07 6.60E-05 329.5 1.50E-07 37.6 0.34 
3 rs4684343 intron 2 0.45 A/G 0.1 0.77 -133.4 8.80E-07 1.90E-02 -194.6 2.50E-05 -65.2 0.02 
2-SNP minor/major allele 
haplotype  
0.13 CG     249 2.00E-09   456.2 1.30E-10 48.4 0.24 
CHR: chromosome, BP: base pair position, MAF: minor allele frequency, beta: change in 11-dehydro TxB2 associated with one copy of the minor allele / 




















































(rs4235745 for PPARGC1B and rs10510230 for CNTN4). D’: the normalised coefficient of linkage disequilibrium between the genotype of the SNP and the 




































































Table 3. Multivariate Cox proportional hazards analysis all significant clinical covariates plus the 
five 11-dehydro TxB2-associated SNPs with a composite cardiovascular endpoint of all ischaemic 
cardiovascular events and procedures. 
All subjects (n=6,199, 477 ischaemic cardiovascular events) 
  HR  95% CI P  
Age (yrs) 1.02 1.01-1.04 7.70E-05 
Male sex 1.54 1.17-2.02 2.00E-03 
Current smoker 1.43 1.17-1.74 0.03 
Type 2 diabetes 1.12 0.92-1.37 5.30E-04 
SBP (mmHg) 1.01 1.00-1.02 0.06 
BMI (kg/m2) 0.98 0.95-1.00 0.25 
HDL (mmol/L) 0.44 0.31-0.62 8.90E-05 
LDL (mmol/L) 1.21 1.10-1.34 1.80E-06 
Amlodipine treatment 0.82 0.68-0.98 1.40E-04 
Aspirin use 4.68 3.84-5.71 < 2e-16 
UK/Ireland cohort 0.56 0.45-0.68 2.10E-08 
rs4235745 (per minor (T) allele) 0.84 0.71-0.99 0.96 
rs32582 (per minor (A) allele) 1.00 0.82-1.21 0.48 
rs10515638 (per minor (T) allele) 1.31 1.08-1.58 0.01 
rs10510230 (per minor (C) allele) 1.25 1.08-1.46 6.90E-03 
rs4684343 (per minor (G) allele) 1.04 0.93-1.17 0.28 
LRT comparison with covariates-only model:  chisq 14.7 on 5 df, p= 0.01 
The primary endpoint was a composite endpoint including all ischaemic cardiovascular events and 
procedures, defined as any of: fatal and non-fatal MI, fatal and non-fatal heart failure, fatal and non-
fatal ischaemic stroke and transient ischaemic attack, angina (stable and unstable), peripheral 




































































hazards model included all SNP genotypes and all covariates. Df: degrees of freedom. SNP statistics 
are based a one-tailed test; where the observed direction of effect is opposite to that predicted, 1-P 
is reported and 95% CI excludes the lower 5% of the distribution. For all SNPs, minor alleles were 
associated with increased 11-dehydro TxB2. SBP: systolic blood pressure. BMI: body mass index. HDL: 
high density lipoprotein cholesterol. LDL: low density lipoprotein cholesterol. Amlodipine treatment 
group: membership of amlodipine (vs atenolol) regime. UK/Ireland: UK/Ireland: UK/Ireland (vs 
Scandinavian) centres participants at UK/Ireland centres vs Scandinavian participants. LRT: likelihood 
ratio test, comprising the chisq (chi squared) comparison of the log likelihoods of the covariates-only 





















































































Figure 1. Association with 11-dehydro TxB2 for the 31,570 SNPs (MAF≥0.05) on the CVD50K chip (A) 
and 2,031,499 SNPs (MAF≥0.05) on the CNV370 chip (B). X-axis: chromosomal location. All SNP 
associations were adjusted for age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, 
LDL, aspirin and anti-hypertensive regimen. The lower dashed lines are the threshold for ‘suggestive’ 
association (P<1E-03), and the upper dashed lines are the Bonferroni threshold for significance 
(P<2.4E-06 for the CNV50K chip and P=1.8E-07 for the CNV370K chip). The most strongly associated 
locus in all subjects on the CVD50K chip, PPARGC1B, is coloured in red and on the CNV370 chip, 





































































Figure 2. Kaplan Meier plot of survival by genotype for the two SNPs independently associated 
with cardiovascular event-free survival, rs10515638 (PPARGC1B) and rs10510230 (CNTN4). 
‘Carriers’: carriers of one or more minor allele. ‘Non carriers’: major allele homozygotes. HR: Hazard 
ratio for the SNP in the multivariate Cox proportional hazards analysis , and corresponding P value 
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